Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: ACU-4429; Drug: matching placebo tablet

• Registration Number: NCT00942240
• Lead Sponsor: Kubota Vision Inc.

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of repeated doses of a new investigational drug (ACU-4429) in healthy human subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2009-07-16
• Study First Submitted QC: 2009-07-17
• Study First Posted: 2009-07-20
• Primary Completion: 2010-04
• Study Completion: 2010-04
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-09
• Last Update Posted: 2012-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• males or females, between 25 and 55 years of age, inclusive
• within BMI range 19 to 32 kg/m2 at Screening
• in good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs;
• clinical laboratory evaluations (including serum for Chem-20 [fasted at least 10 hours], CBC with differential and platelet counts, PT, INR, and aPTT, and UA) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator;
• Males (or female partners of male subjects)and females must be sterile, or agree to use approved contraceptive measures throughout the study period and 45 days after the End of In House Study.
• able to comprehend and willing to sign an Informed Consent Form.

Exclusion Criteria

• significant history or clinical manifestation of any significant metabolic, endocrine, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator);
• history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator;
• history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs, except that appendectomy, hernia repair, and/or cholecystectomy will be allowed;
• history or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant;
• participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in;
• Is currently using, or has recently received treatment with a medication disallowed by the Protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ACU-4429 tablet	ACU-4429	-
matching placebo tablet	matching placebo tablet	-

Primary Outcome Measures

Name	Time	Method
Safety as measured by adverse events, physical exam, ECG, vital signs, laboratory tests and visual tests	20 days

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics as measured by plasma ACU-4429 drug levels	16 days

Trial Locations

Locations (1)

Covance Clinical Research Unit, Inc.; 🇺🇸 Dallas, Texas, United States